Abstract:The considerable increase of investment in research and development by the pharmaceutical industry over the past three decades has not added the number of approved new drugs. An important issue ignored by drug discovery practice is the multi-dimensional interaction network between drugs and their targets. Thus, it is essential to view drug actions through the lens of network biology. In the current study, based on the co-expression network of transcription factors and their downstream genes, we proposed a novel approach, called causal co-expression method with module analysis, to screen drugs with specific target and fewer side effects. We presented a causal co-expression method with module analysis and it could be used in analyzing the microarray data of different drug candidates. At first, the differential wiring value (DW) was calculated to find some causal transcription factors (TFs) by combining with differential expression genes in the regulated networks. After the discovery of the causal TFs, co-expression module analysis method was applied to mine molecular pharmacology pathways around these causal TFs at molecular level. We applied our methods to two drug candidates, Argyrin A and Bortezomib, both with anti-cancer activities. We first obtained some differentially expressed transcription factors of cells treated with Argyrin A or Bortezomib. Nearly all these transcription factors are associated with the tumor suppressor protein p27kip1. Furthermore, module analysis showed that Bortezomib inhibited tumor growth not specifically by cell cycle and cell proliferation pathway, but through many basic metabolic processes which result in cell toxicity. In contrast, Argyrin A had influence on cell cycle, and was involved in DNA damage repair at the same time, showing that Argyrin A was a more suitable drug for anti-cancer treatment. Our study revealed that the causal co-expression method with module analysis was effective and can be used as a tool to evaluate drug candidates.

Insulation of cross-talk between signalingpathways-inspiration for innovative drug design

Network pharmacology approaches for research of Traditional Chinese Medicines

Modeling of Signaling Crosstalk-Mediated Drug Resistance and Its Implications on Drug Combination

Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities

Drug design targeting active posttranslational modification protein isoforms

Network Pharmacology: Exploring the Resources and Methodologies.

Integrated analysis identifies interaction patterns between small molecules and pathways.

[Drug Targets Discovery Based on Dynamic Signal Transduction Networks].

Overview Of Crosstalk Between Multiple Factor Of Transcytosis In Blood Brain Barrier

Computational Approaches for Identifying Signaling Pathways from Molecular Interaction Networks

Cross-talk and interference enhance information capacity of a signaling pathway

Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment

Determining the Balance Between Drug Efficacy and Safety by the Network and Biological System Profile of Its Therapeutic Target

Network-based drug discovery by integrating systems biology and computational technologies

Next generation of network medicine: interdisciplinary signaling approaches

Optimizing drug combination and mechanism analysis based on risk pathway crosstalk in pan cancer

Weak-Binding Molecules Are Not Drugs?-Toward A Systematic Strategy For Finding Effective Weak-Binding Drugs

Causal Co-Expression Method with Module Analysis to Screen Drugs with Specific Target.

Network Output Controllability-Based Method for Drug Target Identification

Pathway Cross-Talk Network Strategy Reveals Key Pathways in Non-Small Cell Lung Cancer

Systematic elucidation of the traditional Chinese medicine prescription Danxiong particles via network pharmacology and molecular docking